The antagonistic effects of atipamezole and yohimbine on stress-related neurohormonal and metabolic responses induced by medetomidine in dogs.

This study aimed to compare the antagonistic effects of atipamezole (40,120, and 320 microg/kg, IM), yohimbine (110 microg/kg, IM), and saline on neurohormonal and metabolic responses induced by medetomidine (20 microg/kg, IM). Five beagle dogs were used in each of the 5 experimental groups in randomized order. Blood samples were taken for 6 h. Medetomidine significantly decreased norepinephrine, epinephrine, insulin, and nonesterified fatty acid levels, and increased plasma glucose levels. Both atipamezole and yohimbine antagonized these effects. The reversal effect of atipamezole was dose-dependency, except on epinephrine. Yohimbine caused prolonged increases in plasma norepinephrine and insulin levels compared to atipamezole, possibly because of its longer half-life elimination. Only yohimbine increased the cortisol levels. Neither glucagon nor lactate levels changed significantly. Based on these findings, when medetomidine-induced sedation is antagonized in dogs, we recommend using atipamezole IM, from 2- to 6-fold the dose of medetomidine, unless otherwise indicated.

[1]  T. Hedner,et al.  Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers , 2005, European Journal of Clinical Pharmacology.

[2]  J. Hubbard,et al.  The pharmacokinetic properties of yohimbine in the conscious rat , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  T. Ambrisko,et al.  Neurohormonal and metabolic effects of medetomidine compared with xylazine in beagle dogs. , 2002, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[4]  J. Arnemo,et al.  The effects of medetomidine and its reversal with atipamezole on plasma glucose, cortisol and noradrenaline in cattle and sheep. , 2000, Journal of veterinary pharmacology and therapeutics.

[5]  W. A. Olson,et al.  Perioperative stress response in the dog: effect of pre-emptive administration of medetomidine. , 2000, Veterinary surgery : VS.

[6]  S. Greene.  Pros and cons of using α-2 agonists in small animal anesthesia practice , 1999 .

[7]  S. M. Hartsfield,et al.  The effect of detomidine and its antagonism with tolazoline on stress-related hormones, metabolites, physiologic responses, and behavior in awake ponies. , 1997, Veterinary surgery : VS.

[8]  O. Vainio,et al.  Atipamezole increases medetomidine clearance in the dog: an agonist-antagonist interaction. , 1995, Journal of veterinary pharmacology and therapeutics.

[9]  M. Berlan,et al.  Evidence for activation of both adrenergic and cholinergic nervous pathways by yohimbine, an alpha2‐adrenoceptor antagonist * , 1995, Fundamental & clinical pharmacology.

[10]  M. Maze,et al.  Alpha‐2 Adrenoceptor Agonists: Defining the Role in Clinical Anesthesia , 1991, Anesthesiology.

[11]  M. Scheinin,et al.  Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. , 1990, British journal of clinical pharmacology.

[12]  A. T. Vähä-Vahe.  The clinical effectiveness of atipamezole as a medetomidine antagonist in the dog. , 1990, Journal of veterinary pharmacology and therapeutics.